Form 4: Hims & Hers Health CEO Andrew Dudum Exercises Options and Sells Shares

Sentiment:

SEC Form 4


CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. on July 3, 2024, according to a Form 4 filing with the SEC.

Summary

  • On July 3, 2024, Andrew Dudum, CEO of Hims & Hers Health, Inc., exercised stock options to acquire 188,888 shares of Class A Common Stock at a price of $2.43 per share.
  • Simultaneously, Dudum sold 94,444 shares at an average price of $20.7478, another 94,444 shares at an average price of $20.7449, and 144,444 shares at an average price of $20.6915.
  • These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
  • Following these transactions, Dudum directly owns 33,502 shares and indirectly owns millions of shares through various trusts.
  • The exercised options were originally for Hims, Inc. shares with an exercise price of $1.10 before the company's business combination in 2021, and converted to Hims & Hers Health, Inc. shares with an exercise price of $2.43.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

Insider transactions are common and closely monitored, especially in publicly traded companies like Hims & Hers Health. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

  • Comparing Andrew Dudum's transactions to other CEOs in the telehealth or healthcare sector, similar patterns of option exercises and share sales under 10b5-1 plans are frequently observed.
  • For example, executives at Teladoc Health or GoodRx often utilize similar strategies to manage their equity compensation.
  • The scale of Dudum's transactions is within the typical range for CEOs of companies with similar market capitalization and growth stage as Hims & Hers Health.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
  • However, the pre-planned nature of the transactions mitigates concerns about insider information being used for personal gain.

Key Dates

DateDescription
10/15/1997Date of Richard M. Dudum Irrevocable 1 U/A
11/01/2021Date of AD 2021 GRAT and AD 2021 GRAT 2
08/10/2021Date of Dudum Family Heritage Trust UAD
09/07/2022Date of AD 2022 GRAT 2
11/28/2022Date of AD 2022 GRAT 3
09/05/2023Date of AD 2023 GRAT
11/29/2023Date of adoption of Rule 10b5-1 trading plan
06/17/2030Expiration date of stock options
07/02/2015Date of Andrew Dudum 2015 Trust
07/03/2024Date of stock option exercise and share sales
07/08/2024Date of signature on the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.